|22nd January 2021||Fund V, L.P. Omega||2,438||Open or private sale||$31.11||$75,846.18|
|22nd January 2021||Fund V, L.P. Omega||7,303||Open or private sale||$30.64||$223,763.92|
|21st January 2021||Fund V, L.P. Omega||264||Open or private sale||$29.98||$7,914.72|
|19th January 2021||Fund V, L.P. Omega||10,732||Open or private sale||$30.10||$323,033.20|
|19th January 2021||Fund V, L.P. Omega||6,506||Open or private sale||$29.95||$194,854.70|
|15th January 2021||Faheem Hasnain||2,098||Grant/award etc.||$0.00|
|15th January 2021||Fund V, L.P. Omega||14,289||Open or private sale||$30.49||$435,671.61|
|14th January 2021||Fund V, L.P. Omega||5,337||Open or private sale||$30.27||$161,550.99|
|14th January 2021||Fund V, L.P. Omega||3,904||Open or private sale||$31.06||$121,258.24|
|13th January 2021||Fund V, L.P. Omega||6,740||Open or private sale||$30.11||$202,941.40|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics. Its primary product candidate is GB001, which is intended for the treatment of moderate-to-severe eosinophilic asthma. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015.